Q-linea AB (publ)

OM:QLINEA Stock Report

Market Cap: SEK 131.8m

Q-linea Valuation

Is QLINEA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of QLINEA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate QLINEA's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate QLINEA's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for QLINEA?

Key metric: As QLINEA is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for QLINEA. This is calculated by dividing QLINEA's market cap by their current revenue.
What is QLINEA's PS Ratio?
PS Ratio37.7x
SalesSEK 3.50m
Market CapSEK 131.79m

Price to Sales Ratio vs Peers

How does QLINEA's PS Ratio compare to its peers?

The above table shows the PS ratio for QLINEA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average8.1x
ICO Iconovo
3.3x48.5%SEK 81.5m
NOSA Nosa Plugs
8.8x38.5%SEK 131.4m
NEOLA Neola Medical
15.7x39.8%SEK 174.0m
GTAB B Glycorex Transplantation
4.7xn/aSEK 107.8m
QLINEA Q-linea
37.7x51.1%SEK 131.8m

Price-To-Sales vs Peers: QLINEA is expensive based on its Price-To-Sales Ratio (37.7x) compared to the peer average (8.1x).

Price to Sales Ratio vs Industry

How does QLINEA's PS Ratio compare vs other companies in the SE Medical Equipment Industry?

12 CompaniesPrice / SalesEstimated GrowthMarket Cap
ARJO B Arjo
0.8x3.6%US$837.96m
CARE Careium
0.8x10.2%US$65.04m
BOUL Boule Diagnostics
0.5x5.6%US$24.11m
ARCOMA Arcoma
0.8x8.3%US$12.68m
QLINEA 37.7xIndustry Avg. 4.7xNo. of Companies12PS048121620+
12 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: QLINEA is expensive based on its Price-To-Sales Ratio (37.7x) compared to the Swedish Medical Equipment industry average (4.8x).

Price to Sales Ratio vs Fair Ratio

What is QLINEA's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

QLINEA PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio37.7x
Fair PS Ratio0.4x

Price-To-Sales vs Fair Ratio: QLINEA is expensive based on its Price-To-Sales Ratio (37.7x) compared to the estimated Fair Price-To-Sales Ratio (0.4x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst QLINEA forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentSEK 1.13
SEK 7.00
+520.6%
57.1%SEK 11.00SEK 3.00n/a2
Nov ’25SEK 2.47
SEK 8.50
+244.1%
29.4%SEK 11.00SEK 6.00n/a2
Oct ’25SEK 2.83
SEK 8.50
+200.9%
29.4%SEK 11.00SEK 6.00n/a2
Sep ’25SEK 3.77
SEK 8.50
+125.5%
29.4%SEK 11.00SEK 6.00n/a2
Aug ’25SEK 3.47
SEK 8.50
+145.0%
29.4%SEK 11.00SEK 6.00n/a2
Jul ’25SEK 3.96
SEK 8.50
+114.9%
29.4%SEK 11.00SEK 6.00n/a2
Jun ’25SEK 2.44
SEK 8.50
+248.4%
29.4%SEK 11.00SEK 6.00n/a2
May ’25SEK 2.60
SEK 8.50
+227.6%
29.4%SEK 11.00SEK 6.00n/a2
Apr ’25SEK 2.14
SEK 8.50
+297.2%
29.4%SEK 11.00SEK 6.00n/a2
Mar ’25SEK 2.11
SEK 10.00
+373.9%
10.0%SEK 11.00SEK 9.00n/a2
Feb ’25SEK 3.24
SEK 10.00
+208.6%
10.0%SEK 11.00SEK 9.00n/a2
Jan ’25SEK 3.70
SEK 10.00
+170.3%
10.0%SEK 11.00SEK 9.00n/a2
Dec ’24SEK 2.80
SEK 10.00
+257.1%
10.0%SEK 11.00SEK 9.00n/a2
Jul ’24SEK 2.89
SEK 11.50
+297.9%
4.3%SEK 12.00SEK 11.00SEK 3.962
Jun ’24SEK 3.49
SEK 28.50
+716.6%
57.9%SEK 45.00SEK 12.00SEK 2.442
May ’24SEK 4.43
SEK 30.50
+588.5%
47.5%SEK 45.00SEK 16.00SEK 2.602
Apr ’24SEK 6.95
SEK 30.50
+338.8%
47.5%SEK 45.00SEK 16.00SEK 2.142

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

Arcoma

SEK 138.4m

Develops, produces, and provides radiology solutions worldwide.

ARCOMA

SEK 10.50

7D

-2.3%

1Y

42.9%

Dignitana

SEK 85.4m

A medical technology company, engages in the development, production, and marketing of medical cooling devices in the United States and internationally.

DIGN

SEK 1.06

7D

-1.9%

1Y

-49.5%

Iconovo

SEK 81.5m

Develops and licenses inhalation medications in Sweden.

ICO

SEK 5.12

7D

-0.8%

1Y

-44.8%